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EDITORIAL 
Predictors of the Adult Respiratory Distress Syndrome 
T HE QUEST for therapeutic agents to pre- vent the adult respiratory distress syn- 
drome (ARDS) has been hampered by the lack 
of accurate predictors of the syndrome. Without 
specific indicators, clinical studies to test the 
efficacy of preventative agents require large 
numbers of patients because only a minority of 
untreated patients will subsequently develop the 
syndrome. An accurate predictor is also neces- 
sary if a preventative intervention becomes avail- 
able that is effective yet has adverse side effects. 
In this case the treatment may still be beneficial 
if its use can be restricted to those patients who 
have a very high likelihood of developing ARDS. 
At the same time the predictor must be sensitive 
enough to allow most patients who are destined 
to develop ARDS to receive the treatment. At 
first analysis, the approach for finding predictors 
would seem to be straightforward. However, 
after further consideration, the problem is found 
to be substantially more complex. 
The first difficulty arises from the manner in 
which the syndrome is defined. Most studies of 
ARDS have used criteria that require the pres- 
ence of a substantial amount of lung injury 
before the diagnosis of ARDS can be made. 
Milder lung injury that is qualitatively similar to 
that which occurs in ARDS certainly exists’ and 
probably has similar pathogenic mechanisms. 
Therefore, any test for predicting ARDS that 
relies upon the presence of specific predisposing 
factors or putative mediators might then appear 
nonspecific because it is also positive in the 
milder cases. 
Another reason for pessimism regarding the 
search for a universally applicable predictor is 
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that there are likely to be many distinct patho- 
genic mechanisms that cause ARDS. There is no 
a priori reason to assume that all cases of A.RDS 
share a single pathway that leads to the increased 
capillary-alveolar permeability. It is possible, 
though, that common mechanisms do exist for 
large subgroups of patients, such as those having 
sepsis syndrome or gastric aspiration. 
Predictive markers of ARDS may reflect 
events occurring anywhere along the pathway 
that leads to lung injury. At one extreme, a test 
might measure a genetic trait that increases the 
likelihood of a patient developing diffuse alveolar 
injury when a particular clinical situation arises. 
Examples of hypothetical genetic variants that 
might predispose to ARDS are those that allow 
excessive activation of inflammatory cascades, 
inadequate down-regulation of ongoing inflam- 
matory processes, or insufficient inhibition of 
injurious products generated during inflamma- 
tion. Although one can conceive of many possible 
genetic or acquired traits that would predispose 
to ARDS, at present no predictive factors of this 
type have been demonstrated. 
Theoretically, the value of a particular predic- 
tive test also depends upon the type of thera- 
peutic intervention that is being considered. For 
example, suppose the events leading to ARDS 





G (mild lung injury) - ARDS 
If a predictive test detects E - F but the planned 
intervention blocks step A - B, the test (even 
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though accurate) might be of little value. Wait- 
ing for the test to become “positive” might be too 
late to start treatment. This is particularly true if 
the pathway up to E is no longer required for 
ARDS to develop once F is activated. This 
concern is similarly applicable to those predictors 
of ARDS that are actually indicators of mild 
lung injury, ie, they detect G in the aforemen- 
tioned hypothetical sequence. Unfortunately, 
many therapeutic agents that are beneficial in 
animal models of ARDS have been tested only 
when given to animals before the process of 
injury is initiated. Their effectiveness has gener- 
ally not been tested when administered after lung 
injury has become manifested. Waiting until 
mild injury occurs might then be too late for 
those patients in whom the process of severe lung 
injury has already been set into motion. The most 
useful predictors would be those that monitor 
events close to the start of the pathogenic 
sequence, yet they must still be specific for 
ARDS. It is possible that a single predictor with 
these characteristics might not exist, and even if 
it does exist, it may be detectable for only a very 
limited period of time during the pathogenic 
process. 
Despite these problems, tests that attempt to 
accurately predict ARDS have been developed 
along several different lines. Excellent epidemi- 
ology studies now exist that estimate the risk of 
developing ARDS in certain clinical situations.2” 
Although the majority of patients who develop 
ARDS usually fit into several diagnostic catego- 
ries, the incidence of ARDS in even the highest 
of these risk groups is only 36%,’ and each 
category represents only a small fraction of the 
total number of ARDS patients. In a study that 
restricted analysis to patients who were already 
intratracheally intubated because of the severity 
of their underlying illness, a subgroup (those 
with “sepsis syndrome”) could be identified that 
had a 47% risk of developing ARDS.3 To further 
improve the utility of this type of an approach, 
multivariate analysis has been used. For exam- 
ple, data from a retrospective study of severely 
ill, intratracheally intubated patients were used 
to develop a predictive test relying on readily 
obtainable information.4 This test when applied 
in a subsequent prospective trial correctly cate- 
gorized 10 of 19 (53%) patients who developed 
ARDS and 61 of 68 (81%) patients who did not. 
In an effort to improve upon these types of 
tests and make them applicable to a broader 
range of patients, the predictive values of various 
laboratory measurements have been investi- 
gated. One of the earlier areas of study involved 
monitoring complement activation. The possibil- 
ity that complement activation might be a useful 
predictor of ARDS arose from reports that neu- 
trophils were sequestered within the lungs of 
patients with ARDS.5,6 The suggestion that 
active components of complement might be 
responsible came from later investigations dem- 
onstrating that complement was activated during 
hemodialysis and was associated with pulmonary 
neutrophil sequestration and hypoxemia.’ Fur- 
thermore, intravascular complement activation 
in laboratory animals caused diffuse lung 
injury.*s9 
In 1980 Hammerschmidt et al reported that 
patients with trauma, sepsis, or shock who subse- 
quently developed ARDS often had signs of 
complement activation.” Of 31 patients at risk 
for ARDS, 6 had active complement fragments 
(CSa-like activity) in their plasma and all 6 
subsequently developed the syndrome. Of 26 
patients without C5a in their plasma, none devel- 
oped ARDS. Unfortunately, more recent studies 
of patients at risk for ARDS have not demon- 
strated that complement activation is a highly 
specific predictor of ARDS.11-‘3 This is not 
entirely surprising considering that complement 
activation is known to occur in many clinical 
situations (eg, septic shock), while ARDS devel- 
ops in only a minority of these cases. The occur- 
rence of lung injury from complement activation 
alone was also called into question with the 
finding that the blood gas alterations seen in 
patients undergoing hemodialysis could be 
totally explained by the loss of carbon dioxide 
across the dialysis membrane and did not neces- 
sarily imply the presence of lung damage.14 Fur- 
thermore, active complement components were 
subsequently shown to be insufficient to cause 
lung injury in the rabbit even though neutrophils 
were still sequestered within the lungs.15 
Although complement activation by itself is not a 
specific predictor of ARDS, it is quite possible 
that in many cases of ARDS, it is an important 
component in the pathogenic process. In these 
situations, additional factors that have yet to be 
fully elucidated are clearly necessary. 
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Alterations within the coagulation system 
have also been suspected of playing a role in the 
lung injury of ARDS.‘6,‘7 Tests that are used to 
diagnose diffuse intravascular coagulation are 
often positive in patients with ARDS and have 
been suggested to be of predictive value for the 
syndrome.” However, prospective studies subse- 
quently demonstrated that critically ill patients 
often have evidence of diffuse intravascular 
coagulation whether or not they go on to develop 
ARDS.19 Fibrinopeptide D, a cleavage product 
of fibrinogen and fibrin, might be more specific 
for ARDS.” Whether the plasma level of this 
fragment has predictive value in patients at risk 
remains to be determined. 
A variety of other mediators have been sug- 
gested as being part of the pathogenic process of 
ARDS based on preliminary human studies and 
data from animal experiments. These mediators 
include the products of arachidonic acid metabo- 
lism,2’ platelet activating factor,22 histamine,23 
and serotonin.24 At present none of these agents 
have been adequately studied to evaluate their 
role as predictors of ARDS. 
Blood neutrophils have been suspected of caus- 
ing lung injury in many but not all cases of 
ARDS.” The proposed mechanism involves acti- 
vation of circulating neutrophils leading to their 
aggregation and sequestration within the lung. 
The activated neutrophils then release agents 
that damage lung parenchyma. A study of 
patients at risk for ARDS revealed that the 
number of circulating leukocytes often decreased 
at the onset of ARDS.26 In addition, neutrophils 
obtained from circulating blood of patients with 
ARDS have been shown to be altered in a 
manner suggesting in vivo activation.27 Detection 
of neutrophil-derived products might therefore 
predict impending ARDS. Lactoferrin, a constit- 
uent of neutrophil granules, has been found to be 
elevated in critically ill patients. In a prospective 
study of 19 patients, the 8 who developed ARDS 
had higher circulating levels of lactoferrin than 
did those without severe lung injury.28 Serum 
lysozyme and breath hydrogen peroxide, other 
products of neutrophils, have also been found to 
be elevated in patients with ARDS.29 It remains 
to be determined from larger studies whether 
these measurements when performed on criti- 
cally ill patients will separate those who progress 
to ARDS from those who do not. 
Plasma concentrations of fibronectin, a glyco- 
protein with opsonic and cell adhesive activities, 
were found to be decreased in patients with 
various critical illnesses such as sepsis and dif- 
fuse intravascular coagulation.30 Because hbro- 
nectin is believed to be important for maintaining 
vascular integrity, its usefulness as a predictor of 
ARDS has been evaluated. A prospective study 
of critically ill, intratracheally intubated patients 
confirmed that plasma fibronectin concentra- 
tions were low when compared to normal, 
healthy individuals.31 However, there was no 
difference in fibronectin levels between those 
critically ill patients who went on to develop 
ARDS and those who did not. 
Various measurements that probably reflect 
mild or early vascular injury have been tested as 
predictors of ARDS. Angiotensin converting 
enzyme, a protease found in relatively high con- 
centrations in pulmonary capillary endothelial 
cells, can be detected in plasma of normal indi- 
viduals. In patients with ARDS, the serum activ- 
ity of angiotensin converting enzyme has been 
found to be 10w.~’ As a predictor of ARDS, the 
test probably lacks adequate sensitivity and spec- 
ificity because levels are low in other lung condi- 
tions such as chronic obstructive pulmonary dis- 
ease and are normal in a significant number of 
patients with ARDS.33 Other pulmonary vascu- 
lar activities, such as the clearance of various 
molecules from blood during transit through the 
lungs, might provide a means to detect early lung 
injury. For example, decreased extraction of 
serotonin34’35 and prostaglandin E,” from circu- 
lating blood of patients with ARDS has been 
described. Whether these tests can reliably pre- 
dict ARDS remains to be seen. 
It is possible that materials obtained from 
other body fluids such as bronchoalveolar lavage 
might provide better predictors. However, the 
inability to easily obtain these specimens from 
nonintubated patients will limit broad scale 
application. For any test to achieve widespread 
use, it must be possible to perform the measure- 
ment quickly and reproducibly at an acceptable 
risk and cost. 
In summary, no single predictor is currently 
available that can be used with high sensitivity 
and specificity to identify patients destined to 
develop ARDS. Multivariate analysis applied to 
the previously mentioned measurements may 
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increase the predictive accuracy of the informa- accurate, clinically applicable predictors of the 
tion present in the currently available epidemio- syndrome. 
logic studies. More likely though, only a better Richard H. Simon 
understanding of the various pathogenic mecha- University of Michigan Medical Center 
nisms of ARDS will lead to the development of Ann Arbor, MI 
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